KYNB
KYNTRA BIO, INC.
Next earnings Aug 10, 2026 (after close) · consensus $-3.34 EPS, $1.24M rev
Last earnings -2.2% on 2026-05-11
$7.24
▲ +4.32%$7.24▲ +34.07%
over 1Y
L $5.22EODHDH $12.43
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+4.3%
1W+5.2%
1M+3.3%
3M+9.9%
YTD-21.0%
1Y+34.1%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Strong net margin (2848.6%); but revenue fell -78.3% YoY.
Revenue (FY2025) $6.44M · FY2025
The read
Middling fundamentals offset by an attractive price (~23713% below fair value) — worth a look on the value angle.
KYNTRA BIO, INC. shows $6.44M in FY2025 revenue (-78.3% YoY), a 2848.6% net margin.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $235M | $141M | $46.8M | $29.6M | $6.44M |
| Gross profit | — | — | — | — | — |
| Operating income | -$289M | -$301M | -$323M | -$150M | -$45.9M |
| Net income | -$290M | -$294M | -$284M | -$47.6M | $183M |
| Diluted EPS | -$3.14 | -$3.14 | -$2.92 | -$11.89 | $45.37 |
| Net margin | -123.3% | -208.7% | -607.3% | -160.6% | 2848.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$56.4M
EV / EBITDA—
EV / Sales8.8
EV / FCF—
P / FCF—
PEG (trailing)0.00
Earnings yield626.1%
FCF yield-16.4%
Quality & risk
ROIC (est.)—
Free cash flow-$4.81M
Total debt$75.0M
Net cash-$27.1M
Altman Z-Score-20.33 distress
Piotroski F-Score4/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-96.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — delisting notice (2026-04-09). Worth a closer look.
Recent filings
all on EDGAR ↗4Period ending 2026-06-122026-06-17open ↗4Period ending 2026-06-122026-06-17open ↗4Period ending 2026-06-122026-06-17open ↗4Period ending 2026-06-122026-06-17open ↗8-KPeriod ending 2026-06-122026-06-16open ↗4Period ending 2026-06-062026-06-09open ↗4Period ending 2026-06-062026-06-09open ↗8-KPeriod ending 2026-06-022026-06-09open ↗4/APeriod ending 2026-05-142026-05-19open ↗4Period ending 2026-05-142026-05-18open ↗SCHEDULE 13G/AFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-12open ↗
Frequently asked
- Is KYNTRA BIO, INC. (KYNB) a buy?
- KYNB currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Strong net margin (2848.6%); but revenue fell -78.3% YoY.
- What is KYNB's fair value?
- A Modified-Graham model based on KYNB's SEC fundamentals estimates a fair value of about $1,724.06. It is an estimate from reported earnings, not a price target.
- Is KYNB overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, KYNB currently appears undervalued relative to its SEC-grounded earnings power.
- What is KYNTRA BIO, INC.'s quality score?
- KYNB scores 56.186274509803916/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000921299, latest 10-Q filed 2026-05-12) · EODHD · as of 6/26/2026, 8:11:17 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.